Division of Uvea-Behçet Unit, Department of Ophthalmology, Erciyes University Medical Faculty, Kayseri, Turkey.
Curr Opin Ophthalmol. 2011 Nov;22(6):508-16. doi: 10.1097/ICU.0b013e32834bbe91.
To alert physician to timely recognition and current treatment of recurrent hypopyon iridocyclitis or panuveitis in ocular Behçet disease (OBD).
Interferon-α, rituximab, intravitreal triamcinolone, and biological response modifiers by tumor necrosis factor inhibitors such as infliximab and adalimumab are being used increasingly for the treatment of severe sight-threatening ocular inflammation including retinal vasculitis and cystoid macular edema (CME).
Biological agents offer tremendous potential in the treatment of OBD. Given that OBD predominantly afflicts the younger adults in their most productive years, dermatologist, rheumatologist, internist, or general practitioners supervising patients with oculo-articulo-oromucocutaneous syndromes should be aware of systemic Behçet disease. Early recognition of ocular involvement is important and such patients should strongly be instructed to visit immediately an ophthalmologist, as uveitis management differs from extraocular involvements with high ocular morbidity from sight-threatening complications due to relapsing inflammatory attacks in the posterior segment of the eye. A single infliximab infusion should be considered for the control of acute panuveitis, whereas repeated long-term infliximab infusions were proved to be more effective in reducing the number of episodes in refractory uveoretinitis with faster regression and complete remission of CME.
提醒医生及时识别和治疗眼型 Behcet 病（OBD）复发性前房积脓性虹膜睫状体炎或全葡萄膜炎。
干扰素-α、利妥昔单抗、玻璃体内曲安奈德以及肿瘤坏死因子抑制剂（如英夫利昔单抗和阿达木单抗）等生物反应调节剂越来越多地用于治疗严重威胁视力的眼部炎症，包括视网膜血管炎和囊样黄斑水肿（CME）。
生物制剂在治疗 OBD 方面具有巨大的潜力。鉴于 OBD 主要影响青壮年人群，在其生产力最高的年龄段发病，因此，负责管理眼-口-生殖器综合征的皮肤科医生、风湿病学家、内科医生或全科医生应了解系统性 Behcet 病。早期识别眼部受累非常重要，应强烈建议此类患者立即就诊眼科医生，因为葡萄膜炎的管理不同于眼外病变，由于后段眼部炎症反复发作，可能导致视力威胁性并发症，眼内发病率较高。对于急性全葡萄膜炎的控制，单次英夫利昔单抗输注即可考虑，而重复长期英夫利昔单抗输注在减少难治性葡萄膜炎发作次数方面更有效，可更快地消退并完全缓解 CME。
